Trifluridine-tipiracil plus bevacizumab ‘feasible alternative’ for unresectable CRC

Trifluridine-tipiracil plus bevacizumab was not superior to capecitabine plus bevacizumab but presented no new safety concerns in patients with unresectable metastatic colorectal cancer who are ineligible for intensive treatment.“The standard first-line treatment for patients with unresectable metastatic colorectal cancer is full-dose doublet or triplet chemotherapy with or without targeted therapy,” Thierry André, MD, professor of medical oncology at Sorbonne University and Saint Antione Hospital in Paris, and colleagues wrote in The Lancet Gastroenterology & Hepatology. “However,Read More

Generated by Feedzy